Podocyte-specific VEGF down-regulation and pathophysiological development

IUBMB Life

Volumn 62, Issue 9, 2010, Pages 677-683

  Zhang, Shuzhi ^a   Ji, Yan ^a   Liu, Xiao ^a   Lu, Xiaodan ^a   Su, Weiheng ^a   Zhang, Di ^a   Hao, Feng ^a   Yi, Fei ^a   Guo, Lei ^a   Li, Xiaomeng ^a   Zheng, Yaowu ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

Nephrin promoter; Pathophysiological development; Podocyte specific down regulation; Transgenic mouse model; VEGF

Indexed keywords

VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; FLUID INTAKE; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GLOMERULUS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; MICTURITION; MORPHOLOGY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PODOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; MUS MUSCULUS;

EID: 78649720895     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.368     Document Type: Article

References (21)

1. Maharaj, A. S. and D'Amore, P. A. (2007) Roles for VEGF in adult. Microvasc. Res. 74, 100-113.
2. Kitamoto, Y., Tokunaga, H., and Tomita K. (1997) Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J. Clin. Invest. 99, 2351-2357.
3. Kim, B. S. and Goligorsky, M. S. (2003) Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease. Korean J. Intern. Med. 18, 65-75.
4. Michaud, J. L., Stitt-Cavanaugh, E., Endlich, N., Endlich, K., De Repentigny, Y., Kothary, R., and Kennedy, C. R. (2010) Mice with podocyte-specific overexpression of wild type alpha-actinin-4 are healthy controls for K256E-alpha-actinin-4 mutant transgenic mice. Transgenic Res. 19, 285-289.
5. Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., Gerber, H. P., Ferrara, N., Barisoni, L., Alpers, C. E., and Quaggin, S. E. (2008) VEGF Inhibition and Renal Thrombotic Microangiopathy. N. Engl. J. Med. 358, 1129-1136. (Pubitemid 351398487)
6. Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., and Quaggin, S. E. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716.
7. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
8. Ostendorf, T., De Vriese, A. S., and Floege, J. (2007) Renal side effects of anti-VEGF therapy in man: A new test system. Nephrol. Dial. Transplant 22, 2778-2780.
9. Levey, S. A., Bajwa, R. S., Picken, M. M., Clark, J. I., Barton, K., and Leehey, D. J. (2008) Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation. NDT Plus 1, 154-156.
10. Ferrara N., Hillan K.J. and Novotny W. (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335.
11. Fedorov, L. M., Tyrsin, O. Y., Krenn, V., Chernigovskaya, E. V., and Rapp, U. R. (2001) Tet-system for the regulation of gene expression during embryonic development. Transgenic Res. 10, 247-258.
12. Grill, M. A., Bales, M. A., Fought, A. N., Rosburg, K. C., Munger, S. J., and Antin, P. B. (2003) Tetracycline-inducible system for regulation of skeletal muscle-specific gene expression in transgenic mice. Transgenic Res. 12, 33-43.
13. Wong, M. A., Cui, S., and Quaggin, S. E. (2000) Identification and characterization of a glomerular-specific promoter from the human nephrin gene. Am. J. Physiol. Renal. Physiol. 279, F1027-F1032.
14. Sambrano, G. R., Weiss, E. J., Zheng, Y. W., Huang, W., and Coughlin, S. R. (2001) Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 74-78.
15. Zhang, Y. W., Bi, L. T., Hou, S. P., Zhao, X. L., Song, Y. L., and Ma, T. H. (2009) Reduced lung water transport rate associated with downregulation of aquaporin-1 and aquaporin-5 in aged mice. Clin. Exp. Pharmacol. Physiol. 36, 734-738.
16. Ishola, D. A. Jr, van der Giezen, D. M., Hahnel, B., Goldschmeding, R., Kriz, W., Koomans, H. A., and Joles, J. A. (2006) In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. Nephrol. Dial. Transplant 21, 591-597.
17. Robinson, C. J. and Stringer, S. E. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell. Sci. 114, 853-865.
18. Shulman, K., Rosen, S., Tognazzi, K., Manseau, E. J., and Brown, L. F. (1996) Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 7, 661-666.
19. Simon, M., Gröne, H. J., Jöhren, O., Kullmer, J., Plate, K. H., Risau, W., and Fuchs, E. (1995) Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 268, F240-F250.
20. Schrijvers, B. F., Flyvbjerg, A., and De Vriese, A. S. (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65, 2003-2017.
21. Pengue, G. and Lania, L. (1996) Kruippel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements. Proc. Natl. Acad. Sci. 93, 1015-1020.